Neurotechnology
Synchron
30-Second Executive Brief
Executive Assessment
Synchron functions as a regional institution within Neurotechnology, backed by 47% sourcing coverage, with a stable competitive position.
- Maintains 3 mapped relationships across the graph
- 47% sourcing coverage across sourced relationships
- Tracked as regional institution within the Neurotechnology category
Executive Snapshot
- Strategic Role
- Regional Institution
- Sourcing Coverage
- 47%
- Ecosystem Influence
- Moderate
- Strategic Momentum
- Insufficient Data
View Methodology →
Computed live from this entity's own relationships and evidence: how many relationships carry at least one linked citation, weighted with citation recency and source type — independent of Strategic Importance, and not a prediction. Not a hand-typed number; recalculated on every read.
Coverage
- Mapped Relationships
- 3
- Technology Domains
- 4
Strategic Implications
- Central node connecting multiple strategic ecosystems
- Directly influences technology and capital flows
- Material relevance to downstream dependency mapping
Top Opportunities
Top Risks
Critical Dependencies
Developer of the Stentrode, a brain-computer interface delivered through blood vessels without open-skull surgery, targeting patients with paralysis. Synchron raised a $200 million Series D in November 2025 (bringing total funding to $345 million) to fund a 2026 pivotal clinical trial -- the study required before Synchron can seek the first FDA premarket approval (PMA) for an implantable BCI -- and is developing a next-generation, higher-channel-count transcatheter interface at a new San Diego engineering hub.
Sources
Every claim traced to a primary source — evidence, recent activity, and insider filing behavior, all in one place.
Evidence
2 sources
- Tech Times — Synchron targets 2026 pivotal trial for first FDA-approved BCInews
- MedTech Dive / Fierce Biotech — Synchron raises $200M Series D to fund 2026 pivotal BCI trialnews
Acquisition & Investment Fit
AI-reasoned, generated only from entities already in InsightNodes's own graph — a hypothetical strategic-fit exercise, not real M&A intelligence or a signal that any deal is planned or in progress.
Relationship Map
The relationships surrounding Synchron — ownership, dependencies, regulation, technology and market context. Click any node to make it the new center, 2 levels deep.
Connection type
Click any node to make it the new center. Scroll to zoom, drag to pan.
The Story So Far
Auto-generated from this entity's dated milestones, relationship updates, and sourced evidence — not AI-written, just sorted.
Synchron's Timeline
A sourced, dated history of Synchron's key moments — founding to present.
Jan 2012 · Founded
Synchron was founded to develop the Stentrode, a blood-vessel-delivered brain-computer interface avoiding open-skull surgery.
Nov 2025 · $200M Series D for 2026 pivotal trial
Synchron raised a $200 million Series D round to fund a 2026 pivotal clinical trial and prepare its first-generation device for commercial launch, bringing total funding to $345 million.